



ASX Announcement

\$20.3 MILLION TO BE RAISED UNDER PLACEMENT WITH UP TO AN ADDITIONAL \$2 MILLION TO BE RAISED UNDER SPP AND US PLACEMENT

- Imricor has raised \$20.3 million via an institutional placement at \$1.68 per CDI
- A security purchase plan (SPP) will be offered to eligible CDI holders in Australia and New Zealand and an additional placement will be offered to certain eligible US stockholders to collectively raise up to \$2 million

21 February 2020 – Melbourne, Australia (20 February 2020 – Minneapolis, United States) – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) announces that it has completed an institutional placement to new and existing sophisticated and professional investors to raise \$20.3 million at A\$1.68 per CHESS Depositary Interest (CDI) (each representing the same number of shares of Class A Common Stock) (**Placement**).

In addition, the Company will launch a security purchase plan for eligible CDI holders in Australia and New Zealand (**SPP**). The Company will also offer certain eligible US stockholders the ability to acquire shares of Class A Common Stock through a placement (**US Placement**). The SPP and US Placement will together raise up to an additional \$2 million.

The new CDIs issued in the capital raising will rank equally with existing Imricor CDIs.

Placement details

The Placement will be completed in a single tranche without stockholder approval, with 12.1 million CDIs (representing the same number of shares of Class A Common Stock) to be issued under the Company's placement capacity in accordance with ASX Listing Rule 7.1.

Moelis Australia Advisory Pty Ltd (**Moelis**) acted as sole lead manager to the Placement and is also sole lead manager to the SPP. Moelis is also settlement underwriting the Placement.

Mr. Steve Wedan, President and CEO of Imricor, stated:

"Now that the Vision-MR catheter has received CE mark, and we are beginning our European launch, this raise provides the capital to promote the successful and risk-mitigated execution of our plans to grow our installed base, expand our product line, expand the geographies in which those products are approved, and broaden their indications for use."

SPP and US Placement details

The Placement will be followed by an offer to existing eligible Australian and New Zealand CDI holders of the Company to participate in a SPP at the same issue price as the Placement (\$1.68 per CDI). The SPP will provide existing eligible CDI holders an opportunity to increase their holding by up to \$30,000. The SPP aims to raise \$1.5 million and is not underwritten. Imricor may (in its absolute discretion) scale-back applications if total demand exceeds \$1.5 million, or raise a higher amount under the SPP to reduce or eliminate the need for scale back.



Existing eligible CDI holders wishing to participate in the SPP should carefully read the SPP Offer Booklet and accompanying form which are expected to be dispatched on or around 28 February 2020. A copy of the SPP Offer Booklet will be available on the ASX website.

Certain existing stockholders in the United States who are “accredited investors” (as defined in Rule 501 of Regulation D) will also be offered the opportunity to participate in a separate placement of Class A Common Stock. The equivalent issue price as the Placement and SPP will apply to the US Placement (but converted to US dollars). The US Placement aims to raise \$0.5 million, but similar to the SPP, the Company may (in its absolute discretion) raise a higher amount if demand exceeds \$0.5 million and the Company has sufficient capacity under ASX Listing Rule 7.1.

The Company does not intend to raise more than A\$2 million collectively under the SPP and US Placement. The funds raised under the SPP and US Placement will be used for the same purposes as the Placement proceeds.

“Our intent with the SPP and US Placement is to provide an opportunity for current non-institutional supporters to also participate in this raise,” commented Wedan. “We hope everyone is as excited as we are to join together as we work to shape the future of interventional medicine.”

Use of proceeds

The funds raised in the Placement, SPP and US Placement will be applied as follows:

	Min. Raise size A\$20.3m		Max. Raise Size A\$22.3m	
Use of proceeds A\$m	A\$m	% of funds	A\$m	% of funds
Sales and marketing ¹	5.0	24.7%	5.6	24.9%
Development, clinical and regulatory ²	11.8	58.1%	13.1	58.9%
Offer Costs	1.1	5.7%	1.3	5.7%
Other working capital ³	2.4	11.5%	2.4	10.5%
Total	20.3	100.0%	22.3	100.0%

1. Includes additional sales and clinical support staff to drive lab adoption and increased catheter utilisation; market research for pipeline products and expanding geographies; and increased tradeshow presence.
2. Includes pipeline product development, expanding approvals across geographies and medical device regulation compliance and product life cycle support.
3. Includes general working capital requirements (including inventory and other support).

Post settlement of the Placement, Imricor’s pro-forma 31 December 2019 cash balance will increase from US\$5.0 million to US\$18.0 million. An additional US\$1.3 million may be collectively raised under the SPP and US Placement. The incremental funds raised under the SPP and US Placement will increase Imricor’s pro-forma 31-December-2019 cash balance by US\$1.3 million to US\$19.3 million.



Key dates for capital raising*

Record date for SPP	Thursday, 20 February 2020
Placement, SPP and US Placement announced to ASX	Friday, 21 February 2020
Settlement of new CDIs issued under Placement	Wednesday, 26 February 2020
Allotment and normal trading of CDIs issued under Placement	Thursday, 27 February 2020
Dispatch of SPP Offer Booklet and SPP Opening Date	Friday, 28 February 2020
SPP Closing Date	Tuesday, 17 March 2020
Allotment of new CDIs under SPP and US Placement	Wednesday, 25 March 2020
Dispatch of holding statements to SPP participants	Thursday, 26 March 2020
SPP and US Placement CDIs commence trading on ASX	Thursday, 26 March 2020

* Please note, the dates set out above are indicative only and are subject to change without notice.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

Further Information

Investors:

Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028

Media:

Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.



Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the US.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor expects to sell its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933, including the rules and regulations promulgated thereunder (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.